Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 3/20 | 0.77 |
| ▸ | ACKR3 | P25106 | 7/20 | 0.61 |
| ▸ | DDT | P30046 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12450543 | 0.88 | MIF (0.71) | MIFACKR3DDTMEN1KMT2A | |
| SCHEMBL18747441 | 0.88 | MIF (0.73) | MIFACKR3DDTMEN1KMT2A | |
| SCHEMBL19147766 | 0.81 | MIF (0.61) | MIFACKR3DDTMEN1KMT2A | |
| SCHEMBL3046758 | 0.77 | SCD (0.77) | MIF | |
| SCHEMBL3477570 | 0.76 | CA1 (0.57) | ACKR3KMT2A | |
| SCHEMBL73126 | 0.76 | RIPK1 (0.62) | MIFACKR3DDTRIPK1LMNA | |
| SCHEMBL17883261 | 0.74 | RIPK1 (0.63) | MIFACKR3RIPK1LMNAALDH1A1 | |
| SCHEMBL17883296 | 0.74 | RIPK1 (0.63) | MIFACKR3RIPK1NPC1RAB9A | |
| SCHEMBL3116253 | 0.74 | MIF (0.59) | MIFACKR3DDTMEN1KMT2A | |
| SCHEMBL17883253 | 0.73 | RIPK1 (0.58) | MIFACKR3DDTRIPK1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120237444-A1 | IODINE RADIOLABELLING METHOD | GE HEALTHCARE LIMITED (GB) | 2012-09-20 | — | — | US | disclosed |
| WO-2011070136-A1 | IODINE RADIOLABELLING METHOD | GE HEALTHCARE LIMITED (GB) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120237444-A1 | IODINE RADIOLABELLING METHOD | BTD, BTN3A1, BTF3 | MIF 1070/4885ACKR3 184/4885DDT 2905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.